Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats a broad range of serious bacterial infections in adult and pediatric patients, particularly when other antibiotics are ineffective.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to healthcare institutions across multiple regions. Clients benefit from reliable logistics, temperature‑controlled shipping, and comprehensive documentation for import compliance.

Meropenem is a carbapenem antibiotic indicated for severe bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with mixed‑flora peritonitis. Complicated urinary tract infections: provides rapid microbiological clearance and symptom resolution in resistant Gram‑negative infections. Hospital‑acquired pneumonia: improves survival and reduces pathogen load in intensive‑care patients. Ventilator‑associated pneumonia: effective against multidrug‑resistant organisms causing ventilator‑related lung infection. Severe sepsis and septic shock: contributes to hemodynamic stabilization by controlling the underlying infection.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset reported in some patients. - Diarrhea: loose stools may occur during therapy. - Infusion site reactions: erythema or phlebitis at the injection site.

Serious or Rare Side Effects: - Seizures: risk increased in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile‑associated colitis: potentially life‑threatening diarrhea.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function assessment: evaluate creatinine clearance and adjust dose in renal impairment. - Allergy assessment: avoid use in patients with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk monitoring: use cautiously in patients with a history of seizures or CNS disease. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks to mother and fetus. - Concomitant drug review: assess for interactions with valproic acid, probenecid, and other nephrotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Valproic acid: may lower seizure threshold and increase risk of seizures. - Probenecid: can increase meropenem plasma concentrations, leading to toxicity. - CNS depressants: additive neurotoxic effects may occur.

Moderate Interactions (Monitor Closely): - Loop diuretics: combined use may enhance renal toxicity. - Aminoglycosides: concurrent nephrotoxic potential requires monitoring of kidney function. - Anticoagulants (warfarin): may affect INR; monitor coagulation parameters.